Drug testing NEMT drivers: who requires it, which test panel, and how a screen works

Who has to test, and who decides

Federal drug testing reaches two groups of NEMT drivers, and a typical sedan or wheelchair van driver belongs to neither. The first group is drivers who must hold a CDL. FMCSA’s testing rule in 49 CFR Part 382 covers them, and on passenger work a CDL comes into play when a vehicle is designed to carry 16 or more people counting the driver, or has a weight rating of 26,001 pounds or more. The second group is drivers working for a contractor of a transit agency funded under federal transit Sections 5307, 5309, or 5311. FTA’s rule in Part 655 follows the money down to the contractor, which is why ADA paratransit contractors test the way transit agencies do.

A minivan or wheelchair van driver doing Medicaid trips usually sits outside both programs. For those drivers, testing comes from the broker contract, the state Medicaid rules, and the company’s own policy. Our guide to whether NEMT drivers need a CDL walks through the vehicle thresholds.

Federal Medicaid law sets only a loose floor. Section 1902(a)(87) of the Social Security Act asks states to confirm that providers have a process “to address any violation of a State drug law.” The words drug test do not appear. Modivcare’s credentialing checklist for out-of-network providers shows how thin that floor is: it asks for proof each year that a driver has not violated state drug laws and gives a criminal background check as the example. A contract can ask for much more, and most of the ones below do.

What brokers and states require

Contracts and state rules differ on test types, frequency, and what happens after a positive, so read the testing clause in each one that applies to you.

• MTM, Pennsylvania. The provider agreement defines a drug screen as a urine test meeting HHS or DOT requirements that covers at least marijuana, cocaine, amphetamines, opioids, and PCP. Driver files must hold pre-employment, post-accident, suspicion, and random results, with random testing “per current FTA regulations.” Refusing to test inside the set window is scored as a positive. A driver with a positive result is barred from MTM members, and no driver may have a positive screen or addiction treatment in the past five years.
• MTM, Rhode Island. The July 2026 handbook makes a five-panel testing program mandatory. It covers new hires and crashes, and its random screens must reach more than a quarter of the drivers each year.
• Louisiana Medicaid. Drivers need a passing five-panel screen, at minimum, once a year and again on suspicion of drug use. Results go from the testing agency directly to the broker. A driver who fails may return only after a substance abuse professional’s final evaluation and return-to-work clearance, and the broker confirms three follow-up screens over the next six months. When a provider reports a crash to the broker, the report must carry the result of a drug screen taken no more than 12 hours after it.
• California charter-party carriers. A fleet that also runs non-medical or other charter work needs a charter-party carrier permit from the Public Utilities Commission, as the California guide explains. Permit holders must test drivers of vehicles seating 15 or fewer under General Order 157-E, Part 10, which follows Parts 40 and 382: pre-employment, post-accident, random, reasonable suspicion, follow-up, and return-to-duty tests, with no pre-employment alcohol test. Because these are not DOT tests, the custody form must be similar to the federal one but a separate form.
• CareOregon. Providers keep a drug-free workplace policy and must send a driver suspected of being under the influence for testing at the provider’s expense. Refusing or testing positive disqualifies the driver.
• Verida and SafeRide Health. Verida’s credentialing documents include up-to-date screens for every owner and driver. SafeRide lists pre-hire drug screenings among driver requirements.

A company working several contracts ends up running the strictest one for everybody, since a driver may carry members for any of them on a given day. Put that program in writing. The drug and alcohol policy template is built for it.

Five-panel, ten-panel, and fentanyl

A five-panel test is the federal standard, and it is the panel MTM’s Pennsylvania and Rhode Island contracts and Louisiana Medicaid name. DOT labs test DOT specimens for five drug classes and are not allowed to test them for anything else (49 CFR 40.82). The table below lists what each class means at the lab, with the initial screening cutoff in nanograms per milliliter of urine from 49 CFR 40.85.

Any sample at or above a screening cutoff goes to a confirmation test, and only a confirmed result is reported as positive.

Panels sold as 9, 10, or 12 drugs are lab products, not a legal standard. If you order one for company tests, get the drug list in writing and check it against every broker’s definition. MTM’s Pennsylvania definition, for example, requires all five classes above, so a panel that swaps one out does not satisfy it.

Fentanyl is the gap people ask about, and it is not in the federal five. HHS added fentanyl and norfentanyl to the panels for federal employee testing on July 7, 2025. DOT proposed the same change for transportation testing on September 2, 2025, with comments closing October 17, 2025. The federal regulatory agenda lists the final rule date as to be determined, and no final rule has been published. Until one is, a DOT test cannot look for fentanyl. A company can add fentanyl to its own non-DOT test, but Part 40 requires the DOT test to be collected first and a separate specimen used for anything extra (49 CFR 40.13).

Lab tests versus instant cups

Drug tests under DOT rules go to a laboratory certified by HHS, which rules out instant cups and on-site kits for CDL and transit drivers (49 CFR 40.81). DOT’s rules also allow oral fluid testing, but HHS’s September 1, 2026 list shows no laboratory certified for oral fluid yet, so DOT drug tests today are urine tests. A DOT rule in force since June 10, 2026 covers the gap: where Part 40 calls for an oral fluid test that cannot be done, the collector takes a urine specimen under direct observation instead.

For company tests, instant cups are legal in many places, with conditions that vary by state.

• Minnesota. Employers must use a certified, accredited, or New York licensed lab, with one exception: on-site oral fluid testing. After a positive, inconclusive, or invalid on-site result, the employee may ask within 48 hours for a lab test at no cost. No employer may discipline or discharge an employee over a screening result that was never confirmed.
• Connecticut. No adverse action may rest on a positive urine screen alone. A second, independent test by gas chromatography and mass spectrometry, or a method the public health commissioner finds at least as reliable, must confirm it, and the tester may not report the unconfirmed positive.

MedlinePlus makes the same point for home kits: a positive rapid result needs a follow-up lab test before anyone relies on it. The practical rule for a NEMT company is to treat an instant cup as a sorting step. A negative can clear a new hire faster. A non-negative goes to a lab before you pull a paycheck or a job.

How a screen moves from the cup to your desk

A lab-based screen passes through several hands before you see a result, and each step protects the driver and you.

1. Collection. The driver gives a specimen at a collection site, and a custody and control form travels with it, so every hand that touches the sample is recorded.
2. Initial screen. The lab runs the screening test. A result under every cutoff is reported as negative.
3. Confirmation. A sample at or above a cutoff is retested by a more specific method. Below the confirmation cutoff, it is negative.
4. MRO review. A confirmed result goes to a medical review officer, a physician who calls the driver before telling you anything. The MRO or the MRO’s staff try the driver’s numbers at least three times over 24 hours. If that fails, the MRO asks your designated employer representative to reach the driver without saying why. Once you have told the driver to call the MRO, the driver has 72 hours. After that, the MRO may verify the result without an interview.
5. Verified result. If a valid prescription explains the result, the MRO reports it as negative. Otherwise you receive a verified positive. For CDL drivers, the MRO also reports a verified positive to the FMCSA Clearinghouse within two business days.

The MRO step is why you should never ask a driver about medications after a non-negative result. The medical conversation belongs to the MRO. Under 49 CFR 40.327, the MRO still has to tell you if a medication makes continued driving a significant safety risk.

Refusals

A refusal is treated as seriously as a positive, and drivers should know what counts before their first test. Under 49 CFR 40.191, these all count as refusing a DOT test:

• Not showing up within a reasonable time when sent for any test other than a pre-employment test.
• Leaving the collection site before the test is complete.
• Not providing a specimen, or not providing enough when the required medical evaluation finds no adequate reason.
• Refusing to allow a directly observed collection when one is required.
• An adulterated or substituted specimen, or admitting to tampering.
• Refusing to cooperate, such as declining to empty pockets or wash hands when the collector asks.

Refusing a company test outside DOT rules is not a DOT refusal, and DOT attaches no consequence to it. Your contracts usually do. MTM’s Pennsylvania agreement counts a refusal within the designated time as a positive result, and CareOregon disqualifies a driver who refuses. Write a deadline into your policy, such as reporting to the collection site within two hours of being told, so “refusal” means the same thing to everyone.

Random testing: rates, pools, and consortiums

Random testing rates are set as a share of your average number of covered drivers over the year, not as a promise that each driver gets tested.

• CDL drivers (FMCSA). Part 382 sets the minimum at 50 percent for drugs and 10 percent for alcohol unless FMCSA announces a change in the Federal Register. Its last change, for 2020, raised the drug rate from 25 to 50 percent after the random positive rate reached 1.0 percent.
• Transit contractors (FTA). FTA kept 2026 at 50 percent for drugs and 10 percent for alcohol. Its verified positive rate for random drug tests was 1.24 percent in 2024.
• Broker contracts. MTM’s Rhode Island handbook wants more than 25 percent of drivers tested at random each year. MTM’s Pennsylvania agreement ties its rate to FTA’s, which puts it at 50 percent for drugs in 2026.

The selection rules matter as much as the rate. FMCSA requires a scientifically valid random method that gives every driver an equal chance at each selection, tests that are unannounced and spread through the year, and a driver who goes to the collection site right away once notified.

A small company does not have to run its own pool. A consortium or third-party administrator puts your drivers in a larger pool, picks names, and sends you the list. FMCSA allows that as long as the pool tests at the right rate and holds only covered drivers. An owner who is the company’s only CDL driver has to be in a pool of two or more, so a consortium is the only practical route. Keep non-DOT drivers in a separate company pool. Federal rules allow only covered employees in a DOT random pool.

What testing costs

The direct cost of a urine screen is modest next to the cost of a mistake. In the rulemaking behind its 2023 oral fluid rule, DOT put a typical urine testing process at about $50, and most commenters told DOT that oral fluid would cost more, not less. DOT’s 2025 fentanyl proposal, using HHS figures, put the added lab screening at $0.23 to $5.00 per specimen and a confirmation at $8 to $25, so expanding a panel is cheap at the lab. For CDL drivers, each Clearinghouse query costs $1.25, and every employer of CDL drivers buys a query plan.

Budget for the extras too. Consortium membership, MRO review fees, and the driver’s paid time at the collection site all sit outside the per-test price. Suspicion tests are on you by contract: MTM’s Pennsylvania agreement and CareOregon’s manual both put them at the provider’s expense. Our guide to reasonable suspicion testing covers how supervisors make that call, and marijuana laws for NEMT drivers covers where state cannabis law limits company tests.

When a driver is off the road

A driver sent for a random or post-accident test is off the road for a few hours, and a positive result can take a driver off the schedule for good. In HealthRide, the dispatch board lets you move that driver’s trips to someone else in one motion, so riders still make their appointments. License and training certificate expiration dates sit with each driver’s other credentials on the fleet page, with reminders before they expire and a warning if dispatch tries to assign a driver whose credential has lapsed.